Skip to main content
SpringerLink
Log in

Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia

Directions for the New Millennium

  • Book
  • © 2001

Overview

Editors:
  1. Azra Raza

    1. MDS Center and Section of Myeloid Diseases, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Suneel D. Mundle

    1. MDS Center and Section of Myeloid Diseases, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Treatment and Research (CTAR, volume 108)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 chapters)

  1. Front Matter

    Pages i-xiv
    Download chapter PDF

  2. Evolving Concepts in Myelodysplastic Syndromes

    • Azra Raza
    Pages 1-24

  3. In Vitro Biology of the Hematopoietic System in Myelodysplastic Syndromes

    • Hector Mayani
    Pages 25-43

  4. Biology of Stem and Myeloid Progenitor Cells in Myelodysplastic Syndromes

    • Lambert F. R. Span, Theo M. de Witte
    Pages 45-63

  5. Novel in Vitro Culture and Ultrastructural Techniques to Study the Biology of Myelodysplastic Syndromes (MDS)

    • Sairah Alvi, Laurie A. Lisak, Vilasini T. Shetty
    Pages 65-79

  6. The Monocytic Component in Myelodysplastic Syndromes

    • Gianluigi Castoldi, Gian Matteo Rigolin
    Pages 81-92

  7. Cytokines and MDS

    • Krishnan Allampallam, Vilasini T. Shetty, Azra Raza
    Pages 93-100

  8. Apoptosis in MDS: A New Perspective

    • Suneel D. Mundle
    Pages 101-109

  9. Molecular, Cytogenetic and Genetic Abnormalities in MDS and Secondary AML

    • Rose Ann Padua, Angela McGlynn, Hugh McGlynn
    Pages 111-157

  10. Stem Cell Transplantation for Myelodysplasia

    • Hans-G. Klingemann, H. Joachim Deeg
    Pages 159-168

  11. Myelodysplastic Syndromes Complicating Hematopoietic Stem Cell Transplantation

    • Athanasios B.-T. Fassas, Guido Tricot
    Pages 169-184

  12. Evolution of Secondary Hematologic Disorders: PREMDS→MDS→sAML

    • Harvey D. Preisler
    Pages 185-230

  13. The Impact of Biology on the Treatment of Secondary AML

    • Ivana Gojo, Judith E. Karp
    Pages 231-255

  14. Special Clinical Concerns/ Problems in the Management of MDS and Sedondary Acute Myeloid Leukemias

    • Parameswaran Venugopal, Sharon Manson, Harvey D. Preisler
    Pages 257-265

  15. MDS and Secondary AML : An Evolutionary Perspective

    • M. William Audeh
    Pages 267-278

  16. Back Matter

    Pages 279-280
    Download chapter PDF
Back to top

Keywords

About this book

Myelodysplastic syndromes are to the bone marrow what pneumonia is to the lungs; the response of an organ to a variety of etiologic insults like aging, toxic exposure, infections and auto-immunity. Among infectious causes alone, pneumonia could be the result of a variety of possible pathogens including bacterial, viral, tuberculous or fungal agents. Similarly, MDS cannot be treated as a single disease. Attempts to harness the inherent complexity of MDS by devising `classifications' which group the various syndromes as one disease is as misguided as saying that a pneumonia is not infectious because it did not respond to antibiotics. Progress in the field will occur faster when we re-analyze this premise. Therefore, until a clearer picture of the disease emerges it is best to treat each of the MDS syndromes as a separate entity. Having no classification is better than a misleading one.
Cancer research has been notable for its periodic cycles of promise and hope, followed by defeat and disappointments. It is not that there is no solution, but that the problem has not been identified precisely. This book is our attempt to define the most crucial questions related to MDS that need to be addressed immediately through logic, analysis and rigorous experimentation. If the emerging problems appear daunting, then instead of being overwhelmed by them, we should follow the advice of the great 20th century thinker Antonio Gramsci, `pessimism of the intellect must be faced with the optimism of will'.

Editors and Affiliations

  • MDS Center and Section of Myeloid Diseases, USA

    Azra Raza, Suneel D. Mundle

Bibliographic Information

  • Book Title: Myelodysplastic Syndromes & Secondary Acute Myelogenous Leukemia

  • Book Subtitle: Directions for the New Millennium

  • Editors: Azra Raza, Suneel D. Mundle

  • Series Title: Cancer Treatment and Research

  • DOI: https://doi.org/10.1007/978-1-4615-1463-3

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Kluwer Academic Publishers 2001

  • Hardcover ISBN: 978-0-7923-7396-4Published: 30 September 2001

  • Softcover ISBN: 978-1-4613-5566-3Published: 23 October 2012

  • eBook ISBN: 978-1-4615-1463-3Published: 06 December 2012

  • Series ISSN: 0927-3042

  • Series E-ISSN: 2509-8497

  • Edition Number: 1

  • Number of Pages: XIV, 280

  • Topics: Oncology, Cancer Research

Publish with us

Policies and ethics

Back to top

Search

Navigation